THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS
https://doi.org/10.21294/1814-4861-2017-16-4-19-25
Abstract
A new generation of aromatase inhibitors and target therapy directed at cycline-dependent kinases 4 and 6 gives a new opportunity to treat metastatic breast cancer. However, the cost of innovative therapy remains high. We present results of the cost-consequence analysis of combination therapy with fulvestrant and palbociclib compared to fulvestrant monotherapy or combination of exemestan and everolimus as a second-line therapy for metastatic breast cancer. It was shown that the combination therapy involving palbociclib increased the length of quality-adjusted life by 191 days and overall survival by almost a year. The use of palbociclib increased the length of quality-adjusted life by 0.06 QALY compared to the combination arm consisting of everolimus. The cumulative 10 year cost per patient was equal to 5.3 million rubles for combination therapy with palbociclib and 3.5 million rubles for combination therapy with everolimus.
About the Authors
S. L. Pavlinsky
I.I. Mechnikov North-Western State Medical University.
Russian Federation
Russian Federation
Pavlinsky Svyatoslav L., MD, DSc, Professor, I.I. Mechnikov North-Western State Medical University.
41, Kirochnaya Street, 191015-Saint-Petersburg, Russia.
P. I. Shabalkin
N.N. Blokhin Russian Cancer Research Center.
Russian Federation
Russian Federation
Shabalkin Pavel I., MD, PhD, Researcher, Department of Perspective Development and International Scientific Relations, N.N. Blokhin Russian Cancer Research Center.
24, Kashirskoe shosse, 115478-Moscow, Russia.
References
1. Avksentieva М.V., Bogin V.I., Derkach Е.V., Omelyaninov V.V., Stenina M.B., Tarakanov A.V., Frolov M.Y. Medical drugs for patients with breast cancer as part of drug provision programs for the population. Pharmacoeconomics and Pharmacoepidemiology. 2016; 9 (3): 8–18. [in Russian]
2. Sherr C.J., Beach D., Shapiro G.I. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2016 Apr; 6 (4): 353–67. doi: 10.1158/2159-8290.CD-15-0894.
3. Coast J. Is economic evaluation in touch with society’s health values? BMJ. 2004; 329 (7476): 1233–1236.
4. Mauskopf J.A., Paul J.E., Grant D.M., Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics. 1998; 13 (3): 277–288
5. Cao Q., Buskens E., Feenstra T., Jaarsma T., Hillege H., Postmus D. Continuous-Time Semi-Markov Models in Health Economic Decision Making: An Illustrative Example in Heart Failure Disease Management. Med Decis Making. 2016 Jan; 36 (1): 59–71. doi: 10.1177/0272989X15593080.
6. Turner N.C., Ro J., André F., Loi S., Verma S., Iwata H., Harbeck N., Loibl S., Huang Bartlett C., Zhang K., Giorgetti C., Randolph S., Koehler M., Cristofanilli M.; PALOMA3 Study Group. Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16; 373 (3): 209–19. doi: 10.1056/NEJMoa1505270.
7. Yardley D.A., Noguchi S., Pritchard K., Burris H.A. 3rd, Baselga J., Gnant M., Hortobagyi G.N., Campone M., Pistilli B., Piccart M., Melichar B., Petrakova K., Arena F.P., Erdkamp F., Harb W.A., Feng W., Cahana A., Taran T., Lebwohl D., Rugo H.S. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progressionfree survival analysis. Adv Ther. 2013 Oct; 30 (10): 870–84. doi: 10.1007/s12325-013-0060-1.
8. Lloyd A., Nafees B., Narewska J., Dewilde S., Watkins J. Health state utilities for metastatic breast cancer. Br J Cancer. 2006 Sep 18; 95 (6): 683–90.
9. OOO «ACME» – information service about the availability of medicines in Saint-Petersburg and Leningrad region [Internet]. [cited 29.11.2016]. URL: http://www.acmespb.ru/drug/eksemestan. [in Russian]
10. Finn R.S., Crown J.P., Ettl J., Schmidt M., Bondarenko I.M., Lang I., Pinter T., Boer K., Patel R., Randolph S., Kim S.T., Huang X., Schnell P., Nadanaciva S., Bartlett C.H., Slamon D.J. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ERpositive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016 Jun 28; 18 (1): 67. doi: 10.1186/s13058-016-0721-5.
11. Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K., Harbeck N., Lipatov O.N., Walshe J.M., Moulder S., Gauthier E., Lu D.R., Randolph S., Diéras V., Slamon D.J. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17; 375 (20): 1925–1936.
12. Rugo H.S., Rumble R.B., Macrae E. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Oncol Pract. 2016 Jun; 12 (6): 583–7. doi: 10.1200/JOP.2016.012914.
13. Kolbin А.S., Maksimkina Е.А., Kurylev А.А. The cost of additional efficacy of antitumor drugs (according to restrictive lists). Remedium. 2016; 11: 56–60. [in Russian]
14. Kaprin A.D., Starinsky V.V., Petrova G.V. Cancer incidence and mortality in Russia in 2015. Moscow, 2017; 250. [in Russian]
15. Kaprin A.D., Starinsky V.V., Petrova G.V. The state of oncological assistance to the population of Russia in 2015. Moscow, 2016; 236. [in Russian]
16. Metastatic Breast Cancer Alliance. Metastatic Breast Cancer Landscape Analysis: Research Report October 2014; 132.
17. Frank G.А., Poddubnaya I.V., Yagudina R.I., Borisov D.А. The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation. Current Oncology. 2013; 15 (3): 48.
Review
For citations:
Pavlinsky S.L., Shabalkin P.I. THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS. Siberian journal of oncology. 2017;16(4):19-25. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-4-19-25
Views:
1399
Email this article 
